IN2014DN10239A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10239A
IN2014DN10239A IN10239DEN2014A IN2014DN10239A IN 2014DN10239 A IN2014DN10239 A IN 2014DN10239A IN 10239DEN2014 A IN10239DEN2014 A IN 10239DEN2014A IN 2014DN10239 A IN2014DN10239 A IN 2014DN10239A
Authority
IN
India
Prior art keywords
relates
compounds
pde4
phosphodiesterase
inhibitors
Prior art date
Application number
Other languages
English (en)
Inventor
Elisabetta Armani
Carmelida Capaldi
Laura Carzaniga
Oriana Esposito
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of IN2014DN10239A publication Critical patent/IN2014DN10239A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
IN10239DEN2014 2012-06-04 2013-05-28 IN2014DN10239A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12170714 2012-06-04
PCT/EP2013/060915 WO2013182451A1 (en) 2012-06-04 2013-05-28 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN10239A true IN2014DN10239A (de) 2015-08-07

Family

ID=48670496

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10239DEN2014 IN2014DN10239A (de) 2012-06-04 2013-05-28

Country Status (11)

Country Link
US (1) US9440954B2 (de)
EP (1) EP2855450B1 (de)
KR (1) KR20150022789A (de)
CN (1) CN104334542A (de)
AR (1) AR091261A1 (de)
BR (1) BR112014029642A2 (de)
CA (1) CA2875421A1 (de)
HK (1) HK1205116A1 (de)
IN (1) IN2014DN10239A (de)
RU (1) RU2637945C2 (de)
WO (1) WO2013182451A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022783A1 (de) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. 1-Phenyl-2-Pyridinylalkyl-Alkoholderivate als Phosphodiesterasehemmer
EP2216327A1 (de) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. (1-Phenyl-2-Pyridin-4-yl)ethyl-benzoate als Phosphodiesterasehemmer
CN106946848B (zh) * 2011-06-06 2022-01-04 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物
CN103827088B (zh) 2011-09-26 2017-10-13 奇斯药制品公司 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物
KR20150090253A (ko) 2012-12-05 2015-08-05 키에시 파르마슈티시 엣스. 피. 에이. Pde4-억제제로서 페닐에틸피리딘 유도체
PL2928869T3 (pl) 2012-12-05 2019-08-30 Chiesi Farmaceutici S.P.A. Pochodne alkoholu 1-fenylo-2-pirydynyloalkilowego jako inhibitory fosfodiesterazy
EP2928880B1 (de) 2012-12-05 2018-02-14 Chiesi Farmaceutici S.p.A. Phenylethylpyridin derivate als pde4-inhibitoren und muscarin rezeptor antagonisten
WO2014086855A1 (en) 2012-12-05 2014-06-12 Chiesi Farmaceutici S.P.A. Phenylethylpyridine derivatives as pde4-inhibitors
TW201710254A (zh) * 2015-06-01 2017-03-16 吉斯藥品公司 胺基酯衍生物
AR104822A1 (es) * 2015-06-01 2017-08-16 Chiesi Farm Spa Derivado de aminoésteres
EP3922247A4 (de) 2019-01-08 2022-10-12 Kyorin Pharmaceutical Co., Ltd. 15-pgdh-inhibitor
CN116082670B (zh) * 2023-04-11 2023-06-27 中国人民解放军军事科学院军事医学研究院 一种含有季膦盐的声响应假性共轭聚合物纳米颗粒的制备方法及其在抗菌领域的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3775684B2 (ja) 1992-07-28 2006-05-17 ローン−プーラン・ロレ・リミテツド 脂肪族−またはヘテロ原子−含有連結基によりアリールまたはヘテロアリールに連結されたフェニル含有化合物
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US20060239927A1 (en) 2003-03-31 2006-10-26 Kyowa Hakko Kogyo Co., Drug for airway administration
WO2008006509A1 (en) * 2006-07-14 2008-01-17 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
NZ578804A (en) * 2007-02-28 2012-04-27 Leo Pharma As Spirocyclic phosphodiesterase inhibitors
EP2022783A1 (de) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. 1-Phenyl-2-Pyridinylalkyl-Alkoholderivate als Phosphodiesterasehemmer
EP2070913A1 (de) 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester-Derivate als Phosphodiesterase-Hemmer
EP2110375A1 (de) * 2008-04-14 2009-10-21 CHIESI FARMACEUTICI S.p.A. Phosphodiesterase-4-Hemmer der Tertiäraminklasse
EP2216327A1 (de) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. (1-Phenyl-2-Pyridin-4-yl)ethyl-benzoate als Phosphodiesterasehemmer
CN106946848B (zh) 2011-06-06 2022-01-04 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇的衍生物
CN103827088B (zh) 2011-09-26 2017-10-13 奇斯药制品公司 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物
WO2013057013A2 (en) 2011-10-21 2013-04-25 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors

Also Published As

Publication number Publication date
CA2875421A1 (en) 2013-12-12
BR112014029642A2 (pt) 2017-06-27
RU2014148316A (ru) 2016-07-27
US20130324501A1 (en) 2013-12-05
WO2013182451A9 (en) 2014-02-06
US9440954B2 (en) 2016-09-13
CN104334542A (zh) 2015-02-04
WO2013182451A1 (en) 2013-12-12
HK1205116A1 (en) 2015-12-11
KR20150022789A (ko) 2015-03-04
EP2855450A1 (de) 2015-04-08
RU2637945C2 (ru) 2017-12-08
EP2855450B1 (de) 2016-07-06
AR091261A1 (es) 2015-01-21

Similar Documents

Publication Publication Date Title
IN2014DN10239A (de)
SG195319A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
JO3181B1 (ar) مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود
WO2013057013A3 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
PH12018501463A1 (en) Pyrimidinyl tyrosine kinase inhibitors
PH12017502141A1 (en) Compounds and their methods of use
MX2015005015A (es) Inhibidores heteroarilo de pde4.
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
NZ700928A (en) Dna-pk inhibitors
WO2013003298A3 (en) Inhibitors of pde10
IN2015DN00127A (de)
IN2013MN00501A (de)
MX2019001011A (es) Compuestos farmaceuticos.
MX2016009352A (es) Inhibidores de quinasa a base de quinolina.
TN2015000574A1 (en) Compounds and compositions as inhibitors of mek
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
MA39824A (fr) Composés azole amido-substitués
GEP201706675B (en) Imidazo-triazine derivatives as pde10 inhibitors
IN2014DN08443A (de)
MX2016015959A (es) Derivados de carbamato los cuales son tanto inhibidores de la enzima fosfodiesterasa 4 (pde4) como antagonistas del receptor muscarinico m3.
MY168958A (en) Intermediates and processes for preparing compounds